Trying to separate three different claims about DSIP: that it is the right molecule, that it is the right dose, and that it does something useful.
What surprised me is how much of the perceived benefit was routine and attention rather than pharmacology.
Sample size, blinding, and who paid for it. Those three questions kill most of the confidence in most of these threads.
What the peptide class does pharmacologically does not require the subjective effect to be large to be real.
I would rather have a narrow conclusion and be right than a broad one and be interesting.
Anyone got a paper worth reading on this rather than a write-up of a paper?
Loose evidence and no evidence are different, and people overcorrect in both directions.
Where does the human data stop and the extrapolation begin? That is the whole thread.
Loose evidence is not nothing, but a washout either side is the only reason to trust your own take.
How long before you can reasonably say something is or is not doing anything?